USPTO Art Unit 1618 Prosecution Statistics

Art Unit Information

Art Unit: 1618
Group: 1610
Tech Center: 1600
Total Cases: 13,152
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19061632BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETINGFebruary 2025June 2025Allow400NoNo
18983625GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGINGDecember 2024June 2025Allow610NoNo
188719621,4-BIS-(2-HYDROXY-BENZYL)-1,4,7-TRIAZACYCLONONANE DERIVATIVES AND SIMILAR COMPOUNDS AS LIGANDS IN IRON(III) COMPLEXES FOR USE AS MRI CONTRAST AGENTSDecember 2024June 2025Allow601NoNo
18927047Stable, concentrated radionuclide complex solutionsOctober 2024May 2025Allow701YesNo
18927034Stable, concentrated radionuclide complex solutionsOctober 2024February 2025Abandon400NoNo
18917080PHARMACEUTICAL FORMULATIONS COMPRISING NALTREXONE AND/OR BUPROPIONOctober 2024April 2025Allow611YesNo
18915867HYDROXYAPATITE-ENCLOSED ZINC PHOSPHATE NANOCOMPOSITEOctober 2024December 2024Allow200YesNo
18905806FORMULATION OF EAR DROPS AND METHODS FOR DELIVERY THEREOF FOR TREATING UPPER RESPIRATORY INFECTIONSOctober 2024April 2025Allow611YesNo
18811352PHARMACEUTICAL COMPOSITION WITH NANOPARTICLE-BASED DRUG DELIVERY COMBINED WITH NON-INVASIVE RADIOGRAPHIC MONITORING MODELAugust 2024February 2025Allow610NoNo
18791270[177LU] LUTETIUM-PSMA I&T COMPOSITION AND DOSIMETRY, KIT, METHOD OF MAKING, AND METHOD OF USING THEREOFJuly 2024April 2025Allow920YesNo
18776861PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOFJuly 2024June 2025Allow1121YesNo
18771562Structural Optimization Method to Improve the Theranostic Performance of Peptide Receptor-Targeted Radionuclide Therapy for CancersJuly 2024April 2025Allow920YesNo
18770529RADIOPHARMACEUTICAL COMPOSITION AND METHODSJuly 2024February 2025Allow711NoNo
18745906COPPER-64 COMPOSITIONS AND FORMULATIONSJune 2024October 2024Allow400YesNo
18745896PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64June 2024March 2025Allow920YesNo
18673814EMBOLIC COMPOSITIONS AND METHODSMay 2024March 2025Allow1011NoNo
18673805EMBOLIC COMPOSITIONS AND METHODSMay 2024March 2025Allow1011NoNo
18648498COMPOSITE ANTIBACTERIAL HYDROGEL DRESSING, PREPARATION METHOD AND APPLICATION THEREOFApril 2024September 2024Allow501NoNo
18646785RADIONUCLIDE LABELED POLYPEPTIDE CONJUGATES AND USES THEREOFApril 2024March 2025Allow1121NoNo
18646526MULTI-MODE IMAGING MARKERSApril 2024December 2024Allow700YesNo
18643088STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOFApril 2024February 2025Allow1020YesNo
18640169ZWITTERIONIC METAL CHELATORSApril 2024June 2025Allow1421YesNo
18640884Stable, concentrated radionuclide complex solutionsApril 2024September 2024Allow500YesNo
18640917Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640907Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640891Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640787CHITOSAN-HYBRIDIZED ZINC PHOSPHATE/HYDROXYAPATITE NANOSTRUCTURE-BASED DRUG DELIVERY SYSTEMApril 2024October 2024Allow610NoNo
18640730STABLE READY TO DILUTE COMPOSITION OF CARFILZOMIBApril 2024June 2025Allow1430NoNo
18637037HYDROPHOBIC TOPICAL COMPOSITIONS AND METHODS FOR PRODUCING SAMEApril 2024January 2025Allow910NoNo
18629717MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOFApril 2024June 2025Allow1410NoNo
18625544Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use ThereofApril 2024March 2025Allow1111YesNo
18625862MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESApril 2024December 2024Allow810YesNo
18624706POLYOLS AND POLYOL-BASED HYDROGELS WITH ANTI-CANCER ACTIVITYApril 2024March 2025Allow1131NoNo
18621526SUPRAMOLECULAR IONIZABLE LIPID MOLECULES WITH HETEROATOMIC TUNING FOR NUCLEIC ACID DELIVERYMarch 2024June 2025Allow1421YesNo
18618520COMPOSITIONS COMPRISING ATICAPRANTMarch 2024September 2024Allow510NoNo
18617245FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOFMarch 2024November 2024Allow800YesNo
18612564LIPIDS AND COMPOSITIONS THEREOFMarch 2024January 2025Allow1010YesNo
18612370CONTROLLED RELEASE FORMULATIONS FOR THE TREATMENT OF MALARIAMarch 2024June 2025Abandon1410NoNo
18612430Formulations Of ApremilastMarch 2024March 2025Allow1210NoNo
18610095METHOD OF PREVENTING THE DEVELOPMENT OF MELANOMAMarch 2024September 2024Allow610NoNo
18607237DEVICE AND METHOD FOR TREATING CANCERMarch 2024April 2025Allow1321YesNo
18692203COSMETIC AND DETERGENT COMPOSITION COMPRISING A POLYMERIC COMPOSITION OF A WATER-SOLUBLE POLYMER ENVELOPED WITHIN ANOTHER POLYMERMarch 2024February 2025Abandon1111NoNo
18604397COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOFMarch 2024August 2024Allow510YesNo
18595720GEL MATERIAL FOR OPHTHALMIC TREATMENT USEMarch 2024June 2025Abandon1510NoNo
18595026USE OF SACCHARIDES FOR CRYOPROTECTION AND RELATED TECHNOLOGYMarch 2024June 2025Abandon1510NoNo
18590452BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSFebruary 2024October 2024Allow820NoNo
18585905IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)February 2024August 2024Allow600NoNo
18582459APPLICATOR AND SYSTEM FOR ADMINISTERING AND DISPENSING FLOWABLE PHARMACEUTICAL PREPARATIONSFebruary 2024June 2025Allow1610NoNo
18436484CARBONIC ANHYDRASE IX TARGETING AGENTS AND METHODSFebruary 2024June 2025Abandon1701NoNo
18435245PHARMACEUTICAL FORMULATIONSFebruary 2024April 2025Abandon1410NoNo
18428591CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGINGJanuary 2024March 2025Allow1300NoNo
18428432NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOFJanuary 2024June 2025Abandon1610NoNo
18415196BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTSJanuary 2024December 2024Allow1120NoNo
18410875Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use ThereofJanuary 2024October 2024Abandon910NoNo
18408490MODIFIED RELEASE NICORANDIL COMPOUND FORMULATIONSJanuary 2024December 2024Abandon1201NoNo
18402112BAMBOO CHARCOAL POWDER-BASED FALSE EYELASHES AND PREPARATION PROCESS THEREOFJanuary 2024March 2025Allow1441NoNo
18392458SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTSDecember 2023July 2024Allow710NoNo
18572198PREPARATION METHOD OF NANOZYME COMPOSITE-BASED HYBRID HYDROGEL EYE DROPDecember 2023July 2024Allow600NoNo
18571259ORAL CARE COMPOSITION, AND PREPARATION METHOD AND APPLICATION THEREOFDecember 2023August 2024Allow810NoNo
18543759NOVEL GASTRORETENTIVE EXTENDED RELEASE DOSAGE FORMDecember 2023May 2025Abandon1610NoNo
18533521PRESSURIZED NANOEMULSIONDecember 2023July 2025Allow1921NoNo
18532785LIPIDS AND LIPID NANOPARTICLE FORMULATIONSDecember 2023June 2024Allow711NoNo
18530764NOVEL, HEAVY VITAMIN B12 DERIVATIVESDecember 2023February 2025Allow1510YesNo
18529587VIRUCIDAL NANOPARTICLES AND USE THEREOF AGAINST INFLUENZA VIRUSDecember 2023May 2025Allow1811NoNo
18526575RADIOLABELLED MGL PET LIGANDSDecember 2023April 2025Allow1610NoNo
18526168Method to Improve the Encapsulation Efficiency and Physicochemical Stability of Ginsenosides Rg3 and CK Nano-emulsionDecember 2023July 2024Allow710NoNo
18526225Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-EnenitrileDecember 2023August 2024Allow900NoNo
18565770MANUFACTURING OF DIMERIC CONTRAST AGENTSNovember 2023March 2025Allow1630YesNo
18520628METHOD FOR MAKING SUPERPARAMAGNETIC IRON OXIDE NANOCARRIERNovember 2023January 2025Allow1410NoNo
18518499APPLICATION OF PHENYL GLUCURONIDE IN PREPARING DRUG FOR PRE-WARNING OF CANCER VIA INDUCED VOLATOLOMICSNovember 2023August 2024Allow910NoNo
18516167NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERSNovember 2023May 2025Allow1701YesNo
18513283MANNOSE DERIVATIVE AND APPLICATION THEREOFNovember 2023July 2024Allow820NoNo
18512708RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERSNovember 2023November 2024Allow1221NoNo
18511854STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOFNovember 2023February 2024Allow300YesNo
18505688COMPLEX COMPRISING A PSMA-TARGETING COMPOUND LINKED TO A LEAD OR THORIUM RADIONUCLIDENovember 2023March 2025Allow1610YesNo
18503465PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOFNovember 2023February 2025Abandon1510NoNo
18499758METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXESNovember 2023August 2024Allow911YesNo
18289027PEPTIDE LIGAND TARGETING CARBONIC ANHYDRASE IX, PEPTIDE CONSTRUCT COMPRISING SAME, AND USES THEREOFOctober 2023January 2025Allow1401NoNo
183836484-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)BENZOIC ACID AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow501NoNo
18491647METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOFOctober 2023March 2025Allow1701NoNo
18380822METHOD OF USING ADENOSINE AND DIPYRIDAMOLE FOR PHARMACOLOGIC STRESS TESTING, WITH SPECIFIC COMPOSITIONS, UNIT DOSAGE FORMS AND KITSOctober 2023June 2025Abandon2010NoNo
18483007TABLET FOR ORAL SUSPENSIONOctober 2023March 2025Allow1710NoNo
18376038SKIN SOLUTION WITH SOLUBILIZED BAKUCHIOLOctober 2023June 2025Allow2010NoNo
18478524ORAL POUCH PRODUCTSeptember 2023December 2024Allow1530NoNo
18374645COMPOSITIONS COMPRISING A THERMOREVERSIBLE HYDROGEL, AND HAVING AN EXTENDED IN-USE PERIODSeptember 2023July 2024Abandon1001NoNo
18474209FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOFSeptember 2023April 2025Allow1920NoNo
18368695ABSORBABLE SUTURE CONTAINING HYALURONIC ACID AND MANUFACTURING METHOD THEREFORSeptember 2023May 2025Abandon2030YesNo
18244155TOPICAL AMLODIPINE SALTS FOR THE TREATMENT OF ANORECTAL DISEASESSeptember 2023January 2025Abandon1610NoNo
18243735STABLE SOLID FINGOLIMOD DOSAGE FORMSSeptember 2023March 2025Abandon1810NoNo
18462701FIBRIN PARTICLES AND METHODS OF MAKING THE SAMESeptember 2023May 2025Allow2011NoNo
18548546COMPOUND TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN, AND PREPARATION METHOD AND APPLICATION THEREOFAugust 2023December 2023Allow400NoNo
18456931PSMA TARGETED COMPOUNDS AND USES THEREOFAugust 2023April 2024Allow720YesNo
18238966PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64August 2023March 2024Allow710NoNo
18238972PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64August 2023October 2024Allow1430NoNo
18238951PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64August 2023July 2024Allow1111YesNo
18456300PHARMACEUTICAL COMPOSITION WITH NANOPARTICLE-BASED DRUG DELIVERY COMBINED WITH NON-INVASIVE RADIOGRAPHIC MONITORING MODELAugust 2023August 2024Allow1221YesNo
18452312CONJUGATES AND THEIR USE AS IMAGING AGENTSAugust 2023January 2025Allow1730YesNo
18546989DUAL-TARGETING COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOFAugust 2023March 2024Allow710NoNo
18450737EQUILIBRIUM ADSORPTION METHOD FOR MAKING A SILICA NANOCARRIER SPION COMPOSITIONAugust 2023November 2023Allow310NoNo
18451030Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK InhibitorAugust 2023September 2024Allow1310NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1618.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
505
Examiner Affirmed
341
(67.5%)
Examiner Reversed
164
(32.5%)
Reversal Percentile
50.1%
Higher than average

What This Means

With a 32.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1996
Allowed After Appeal Filing
415
(20.8%)
Not Allowed After Appeal Filing
1581
(79.2%)
Filing Benefit Percentile
7.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1618 - Prosecution Statistics Summary

Executive Summary

Art Unit 1618 is part of Group 1610 in Technology Center 1600. This art unit has examined 13,152 patent applications in our dataset, with an overall allowance rate of 48.1%. Applications typically reach final disposition in approximately 39 months.

Comparative Analysis

Art Unit 1618's allowance rate of 48.1% places it in the 5% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1618 receive an average of 2.47 office actions before reaching final disposition (in the 91% percentile). The median prosecution time is 39 months (in the 7% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.